{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:04:35Z","timestamp":1774638275477,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1038\/ncponc0019","type":"journal-article","created":{"date-parts":[[2004,10,29]],"date-time":"2004-10-29T17:27:45Z","timestamp":1099070865000},"page":"32-38","source":"Crossref","is-referenced-by-count":9,"title":["Allogeneic hematopoietic stem-cell transplantation: the next generation of therapy for metastatic renal cell cancer"],"prefix":"10.1038","volume":"1","author":[{"given":"Manit","family":"Arya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitendra RH","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncponc0019_CR1","unstructured":"Cancer Research UK (2004) Statistics. [ http:\/\/www.cruk.co.uk\/aboutcancer\/statistics\/incidence ] (accessed 16 September 2004)"},{"key":"BFncponc0019_CR2","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1016\/S0140-6736(98)01041-1","volume":"352","author":"NJ Vogelzang","year":"1998","unstructured":"Vogelzang NJ and Stadler WM (1998) Kidney cancer. Lancet 352: 1691\u20131696","journal-title":"Lancet"},{"key":"BFncponc0019_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJM199609193351207","volume":"335","author":"RJ Motzer","year":"1996","unstructured":"Motzer RJ et al. (1996) Renal cell carcinoma. N Engl J Med 335: 865\u2013875","journal-title":"N Engl J Med"},{"key":"BFncponc0019_CR4","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1200\/JCO.1998.16.6.2261","volume":"16","author":"JP Kavolius","year":"1998","unstructured":"Kavolius JP et al. (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261\u20132266","journal-title":"J Clin Oncol"},{"key":"BFncponc0019_CR5","first-page":"42","volume":"22","author":"A Yagoda","year":"1995","unstructured":"Yagoda A et al. (1995) Chemotherapy for advanced renal-cell carcinoma: 1983\u20131993. Semin Oncol 22: 42\u201360","journal-title":"Semin Oncol"},{"key":"BFncponc0019_CR6","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","volume":"163","author":"RJ Motzer","year":"2000","unstructured":"Motzer RJ and Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408\u2013417","journal-title":"J Urol"},{"key":"BFncponc0019_CR7","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1200\/JCO.1990.8.9.1504","volume":"8","author":"WJ Hrushesky","year":"1990","unstructured":"Hrushesky WJ et al. (1990) Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8: 1504\u20131513","journal-title":"J Clin Oncol"},{"key":"BFncponc0019_CR8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0094-0143(21)00489-4","volume":"20","author":"A Yagoda","year":"1993","unstructured":"Yagoda A et al. (1993) Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 20: 303\u2013321","journal-title":"Urol Clin North Am"},{"key":"BFncponc0019_CR9","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/0959-8049(92)90139-S","volume":"28A","author":"SD Fossa","year":"1992","unstructured":"Fossa SD et al. (1992) Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group. Eur J Cancer 28A: 878\u2013880","journal-title":"Eur J Cancer"},{"key":"BFncponc0019_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0094-0143(03)00031-4","volume":"30","author":"MI Milowsky","year":"2003","unstructured":"Milowsky MI and Nanus DM (2003) Chemotherapeutic strategies for renal cell carcinoma. Urol Clin North Am 30: 601\u2013609","journal-title":"Urol Clin North Am"},{"key":"BFncponc0019_CR11","first-page":"177","volume":"27","author":"RJ Amato","year":"2000","unstructured":"Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177\u2013186","journal-title":"Semin Oncol"},{"key":"BFncponc0019_CR12","first-page":"207","volume":"7","author":"EA Klein","year":"1989","unstructured":"Klein EA (1989) The multidrug resistance gene in renal cell carcinoma. Semin Urol 7: 207\u2013214","journal-title":"Semin Urol"},{"key":"BFncponc0019_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1073\/pnas.84.1.265","volume":"84","author":"AT Fojo","year":"1987","unstructured":"Fojo AT et al. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265\u2013269","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFncponc0019_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000474284","volume":"24","author":"S Naito","year":"1993","unstructured":"Naito S et al. (1993) Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 24: 156\u2013160","journal-title":"Eur Urol"},{"key":"BFncponc0019_CR15","first-page":"1063","volume":"12","author":"M Volm","year":"1992","unstructured":"Volm M et al. (1992) Expression of several resistance mechanisms in untreated human kidney and lung carcinomas. Anticancer Res 12: 1063\u20131067","journal-title":"Anticancer Res"},{"key":"BFncponc0019_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0022-5347(17)73147-3","volume":"20","author":"HC Bumpus","year":"1928","unstructured":"Bumpus HC (1928) The apparent disappearance of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol 20: 185","journal-title":"J Urol"},{"key":"BFncponc0019_CR17","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1002\/1097-0142(19810415)47:8<2102::AID-CNCR2820470833>3.0.CO;2-K","volume":"47","author":"DJ Fairlamb","year":"1981","unstructured":"Fairlamb DJ (1981) Spontaneous regression of metastases of renal cancer: a report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 47: 2102\u20132106","journal-title":"Cancer"},{"key":"BFncponc0019_CR18","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0002-9440(10)65007-9","volume":"156","author":"A Albini","year":"2000","unstructured":"Albini A et al. (2000) Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 156: 1381\u20131393","journal-title":"Am J Pathol"},{"key":"BFncponc0019_CR19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0094-0143(21)00487-0","volume":"20","author":"MP Wirth","year":"1993","unstructured":"Wirth MP (1993) Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 20: 283\u2013295","journal-title":"Urol Clin North Am"},{"key":"BFncponc0019_CR20","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1200\/JCO.1993.11.7.1368","volume":"11","author":"LM Minasian","year":"1993","unstructured":"Minasian LM et al. (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11: 1368\u20131375","journal-title":"J Clin Oncol"},{"key":"BFncponc0019_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1200\/JCO.1991.9.5.832","volume":"9","author":"JA Neidhart","year":"1991","unstructured":"Neidhart JA et al. (1991) Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol 9: 832\u2013836","journal-title":"J Clin Oncol"},{"key":"BFncponc0019_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","volume":"271","author":"SA Rosenberg","year":"1994","unstructured":"Rosenberg SA et al. (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907\u2013913","journal-title":"JAMA"},{"key":"BFncponc0019_CR23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJM199804303381805","volume":"338","author":"S Negrier","year":"1998","unstructured":"Negrier S et al. (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272\u20131278","journal-title":"N Engl J Med"},{"key":"BFncponc0019_CR24","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/35077246","volume":"411","author":"SA Rosenberg","year":"2001","unstructured":"Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380\u2013384","journal-title":"Nature"},{"key":"BFncponc0019_CR25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","volume":"304","author":"PL Weiden","year":"1981","unstructured":"Weiden PL et al. (1981) Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529\u20131533","journal-title":"N Engl J Med"},{"key":"BFncponc0019_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0140-6736(84)92009-9","volume":"2","author":"RP Gale","year":"1984","unstructured":"Gale RP and Champlin RE (1984) How does bone marrow transplantation cure leukaemia? Lancet 2: 28\u201330","journal-title":"Lancet"},{"key":"BFncponc0019_CR27","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","volume":"76","author":"HJ Kolb","year":"1990","unstructured":"Kolb HJ et al. (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 76: 2462\u20132465","journal-title":"Blood"},{"key":"BFncponc0019_CR28","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"HJ Kolb","year":"1995","unstructured":"Kolb HJ et al. (1995) Graft-versus-leukemia effect of donor lymphocyte tranfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86: 2041\u20132050","journal-title":"Blood"},{"key":"BFncponc0019_CR29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood.V88.4.1501.bloodjournal8841501","volume":"88","author":"B Eibl","year":"1996","unstructured":"Eibl B et al. (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88: 1501\u20131508","journal-title":"Blood"},{"key":"BFncponc0019_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1200\/JCO.1998.16.3.986","volume":"16","author":"NT Ueno","year":"1998","unstructured":"Ueno NT et al. (1998) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16: 986\u2013993","journal-title":"J Clin Oncol"},{"key":"BFncponc0019_CR31","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","volume":"91","author":"S Slavin","year":"1998","unstructured":"Slavin S et al. (1998) Nonmyeloablative stem cell transplantation and cell therapy as alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 91: 756\u2013763","journal-title":"Blood"},{"key":"BFncponc0019_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1182\/blood.V99.1.75","volume":"99","author":"P Corradini","year":"2002","unstructured":"Corradini P et al. (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99: 75\u201382","journal-title":"Blood"},{"key":"BFncponc0019_CR33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<564::AID-IJC23>3.0.CO;2-6","volume":"66","author":"A Caignard","year":"1996","unstructured":"Caignard A et al. (1996) In situ demonstration of renal cell carcinoma-specific T-cell clones. Int J Cancer 66: 564\u2013570","journal-title":"Int J Cancer"},{"key":"BFncponc0019_CR34","first-page":"3078","volume":"58","author":"P Jantzer","year":"1998","unstructured":"Jantzer P and Schendel DJ (1998) Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 58: 3078\u20133086","journal-title":"Cancer Res"},{"key":"BFncponc0019_CR35","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1056\/NEJM200009143431101","volume":"343","author":"R Childs","year":"2000","unstructured":"Childs R et al. (2000) Regression of metastatic renal cell carcinoma after non-myeloablative allogeneic peripheral-blood stem cell transplantation. N Engl J Med 343: 750\u2013758","journal-title":"N Engl J Med"},{"key":"BFncponc0019_CR36","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2002.08.068","volume":"20","author":"BI Rini","year":"2002","unstructured":"Rini BI et al. (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20: 2017\u20132024","journal-title":"J Clin Oncol"},{"key":"BFncponc0019_CR37","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/cncr.10491","volume":"94","author":"P Pedrazzoli","year":"2002","unstructured":"Pedrazzoli P et al. (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94: 2409\u20132415","journal-title":"Cancer"},{"key":"BFncponc0019_CR38","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1182\/blood.V99.11.4234","volume":"99","author":"M Bregni","year":"2002","unstructured":"Bregni M et al. (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99: 4234\u20134236","journal-title":"Blood"},{"key":"BFncponc0019_CR39","first-page":"198","volume":"102","author":"M Bregni","year":"2003","unstructured":"Bregni M et al. (2003) Graft versus tumor effect following reduced intensity allogeneic stem cell transplantation in renal cell cancer: on behalf of the EBMT Solid Tumor Working Party [abstract]. Blood 102: 198","journal-title":"Blood"},{"key":"BFncponc0019_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood-2003-07-2236","volume":"103","author":"D Blaise","year":"2004","unstructured":"Blaise D et al. (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103: 435\u2013441","journal-title":"Blood"},{"key":"BFncponc0019_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0094-0143(03)00025-9","volume":"30","author":"D Drachenberg","year":"2003","unstructured":"Drachenberg D and Childs RW (2003) Allogeneic stem cell transplantation as immunotherapy for renal cell carcinoma: from immune enhancement to immune replacement. Urol Clin North Am 30: 611\u2013622","journal-title":"Urol Clin North Am"},{"key":"BFncponc0019_CR42","doi-asserted-by":"crossref","unstructured":"Maloney DG et al. (2002) Non-myeloablative transplantation. Hematology (Am Soc Hematol Educ Program) 392\u2013421","DOI":"10.1182\/asheducation-2002.1.392"},{"key":"BFncponc0019_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1097\/00007890-199401000-00015","volume":"57","author":"SD Nimer","year":"1994","unstructured":"Nimer SD et al. (1994) Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation: a randomized controlled trial. Transplantation 57: 82\u201387","journal-title":"Transplantation"},{"key":"BFncponc0019_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1182\/blood.V97.3.631","volume":"97","author":"S Giralt","year":"2001","unstructured":"Giralt S et al. (2001) Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 97: 631\u2013637","journal-title":"Blood"},{"key":"BFncponc0019_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","volume":"99","author":"R Chakraverty","year":"2002","unstructured":"Chakraverty R et al. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99: 1071\u20131078","journal-title":"Blood"},{"key":"BFncponc0019_CR46","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S0301-472X(00)00655-X","volume":"29","author":"A Nagler","year":"2001","unstructured":"Nagler A et al. (2001) Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 29 362\u2013370","journal-title":"Exp Hematol"},{"key":"BFncponc0019_CR47","first-page":"2254","volume":"7","author":"M Bornhauser","year":"2001","unstructured":"Bornhauser M et al. (2001) Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 7: 2254\u20132262","journal-title":"Clin Cancer Res"},{"key":"BFncponc0019_CR48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.bmt.1703811","volume":"31","author":"P Hentschke","year":"2003","unstructured":"Hentschke P et al. (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31: 253\u2013261","journal-title":"Bone Marrow Transplant"},{"key":"BFncponc0019_CR49","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/S0140-6736(98)11135-2","volume":"353","author":"M Sykes","year":"1999","unstructured":"Sykes M et al. (1999) Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353: 1755\u20131759","journal-title":"Lancet"},{"key":"BFncponc0019_CR50","first-page":"2512","volume":"100","author":"LP Koh","year":"2002","unstructured":"Koh LP et al. (2002) Campath-1H, T cell depleted nonmyeloablative peripheral blood stem cell transplantation from 3-6\/6 HLA matched family members [abstract]. Blood 100: 2512","journal-title":"Blood"},{"key":"BFncponc0019_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(04)01387-7","volume":"5","author":"M Satoh","year":"2004","unstructured":"Satoh M et al. (2004) Haploidentical, non-myeloablative stem cell transplantation for advanced renal cell cancer. Lancet Oncol 5: 125\u2013126","journal-title":"Lancet Oncol"},{"key":"BFncponc0019_CR52","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-03-0754","volume":"10","author":"S Miyakoshi","year":"2004","unstructured":"Miyakoshi S et al. (2004) Successful engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with advanced hematological diseases. Clin Cancer Res 10: 3586\u20133592","journal-title":"Clin Cancer Res"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc0019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0019","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc0019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:35:37Z","timestamp":1684442137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["BFncponc0019"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0019","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}